Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Jill C. Milne, Philip Lambert, Simon Schenk et al. · Nature · 2007
Cited by 1,701 works. doi:10.1038/nature06261
Authors
- Jill C. Milne
- Philip Lambert
- Simon Schenk
- David P. Carney
- Jesse Joshua Smith
- Lei Jin
- Olivier Boss
- Robert B. Perni
- Chi B. Vu
- Jean E. Bemis
- Roger L. Xie
- Jeremy S. Disch
- Pui Yee Ng
- Joseph J. Nunes
- Amy V. Lynch
- Hongying Yang
- Heidi L. Galonek
- Kristine Israelian
- Wendy Choy
References
- Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
- hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
- Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
- Resveratrol improves health and survival of mice on a high-calorie diet
- The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms
- Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
- Requirement of NAD and SIR2 for Life-Span Extension by Calorie Restriction in Saccharomyces cerevisiae
- Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α
- Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
- Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase